Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France

Health Economics

Volumn 13, Issue 3, 2004, Pages 227-238

  Berchi, Célia ^a,b   Bouvier, Véronique ^a   Réaud, Jean Marie ^c   Launoy, Guy ^a  

^a INSERM   (France)

^b UNIVERSITÉ DE CAEN   (France)

^c Controle Med de l'Assurance Maladie ^*  (France)

Author keywords

Colorectal cancer; Cost effectiveness; Fecal occult blood test; Mass screening; Model simulation

Indexed keywords

GUAIAC;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SCREENING; COLORECTAL CANCER; COMPUTER PROGRAM; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FECES ANALYSIS; FRANCE; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; IMMUNOLOGICAL TECHNIQUE; INTERMETHOD COMPARISON; LABORATORY AUTOMATION; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MASS SCREENING; MATHEMATICAL MODEL; OCCULT BLOOD; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY;

AGED; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FRANCE; HEALTH SERVICES RESEARCH; HUMANS; MALE; MASS SCREENING; MIDDLE AGED;

EID: 1442325536     PISSN: 10579230     EISSN: None     Source Type: Journal    
DOI: 10.1002/hec.819     Document Type: Article

References (27)

1. Launoy G, Grosclaude P, Pienkowski P et al. Les cancers digestifs en France. Comparaison de l'incidence dans 7 départements et estimation de l'incidence pour la France entière. Gastroenterol Clin Biol 1992; 16: 633-8.
2. Faivre J, Grosclaude P, Launoy G, Arveux P et al. Les cancers digestifs en France. Distribution géographique et estimation de l'incidence nationale. Gastroenterol Clin Biol 1997; 21: 174-180.
3. Mandel JS, Bond JH, Church TR et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 1993; 328: 1365-1371.
4. Hardcastle JD, Chamberlain JO, Robinson MH et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477.
5. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471.
6. Castiglione G, Sala P, Ciatto S et al. Comparative analysis of results of guaiac and immunochemical tests for faecal occult blood in colorectal cancer screening in two oncological institutions. Eur J Cancer Prev 1994; 3: 399-405.
7. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal cancer screening. N Engl J Med 1996; 334: 155-159.
8. Saito H. Screening for colorectal cancer by immunochemical fecal occult blood testing. Jpn J Cancer Res 1996; 87: 1011-1024.
9. Sieg A, Hertel A, John MR, Lüthgens K, Schmidt-Gayk H. Screening for colorectal neoplasms with a new immunological human faecal haemoglobin and albumin test. Eur J Cancer Prev 1998; 7: 279-285.
10. Sonnenberg FA, Beck JA. Markov models in medical decision making: a practical guide. Med Decision Making 1993; 13: 322-338.
11. Launoy G, Herbert C, Vallée JP et al. Le dépistage de masse du cancer colorectal en France. Expérience auprès de 165 000 personnes dans le Calvados. Gastroenterol Clin Biol 1996; 20: 228-236.
12. Arminski TC, Mac Lean DW. Incidence and distribution of adenomatous adenomas of the colon and rectum based on 1000 autopsy examinations. Dis Colon Rectum 1964; 7: 249-261.
13. Rickert RR, Auerbach O, Garfinkel L, Hammond EC, Frasca JM. Adenomatous lesions of the large bowel: an autopsy survey. Cancer 1979; 43: 1847-1857.
14. Vatn MH, Stalsberg H. The prevalence of adenomas of the large intestine in Oslo: an autopsy study. Cancer 1982; 49: 819-825.
15. Bouvier V, Herbert C, Launoy G. Stage of extension and treatement for colorectal cancer after a negative test and among non-responders in mass screening with guaiac faecal occult blood test: a french experience. Eur J Cancer Prev 2001; 10: 323-326.
16. Stryker SJ, Wolff BG, Culp CE et al. Natural history of untreated colonic adenomas. Gastroenterology 1987; 93: 1009-13.
17. Kerjosse R, Tamby I. La situation démographique en 1994. In Démographie-Société No 51-52. INSEE, Paris, 1996.
18. Tran DQ, Rosen L, Kim R et al. Actual colonoscopy: what are the risks of perforation? Am. Surg 2001; 67(9): 845-7.
19. Zappa M, Castiglione G, Paci E et al. Measuring interval cancers in population-based screening using different assays of fecal occult blood testing: the district of Florence experience. Int J Cancer 2001; 92: 151-54.
20. Comité pour le dépistage du cancer de l'intestin dans le Calvados. Campagne 1991-1992-1993, 3 ans pour convaincre? Rapport final, mars 1994.
21. Bouvier V, Réaud JM, Gignoux M, Launoy G. Cost of diagnostic and therapeutic management of colorectal cancer according to stage at diagnosis in the Calvados department (France). Eur J Health Econ. in press.
22. Frazier AL, Colditz GA, Fuchs CS, Kuntz KM. Cost-effectiveness of screening for colorectal cancer in the general population. J Am Med Assoc 2000; 284(15): 1954-1961.
23. Khandker RK, Dulski JD, Kilpatrick JB, Ellis RP, Mitchell JB, Baine WB. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Intl J Technol Assess Health Care 2000; 16(3): 799-810.
24. Arveux P, Lejeune C, Pitard A. Coûts d'un programme efficient de dépistage du cancer du côlon. Gastroenterol Clin Biol 1998; 22: S49-S55.
25. Bouvier V, Launoy G, Herbert C, Lefevre H, Maurel J, Gignoux M. Colorectal cancer after a negative Haemoccult II â test and programme sensitivity after a first round of screening:the experience of the Department of Calvados (France). Br J Cancer 1999; 81(2): 305-309.
26. Faivre J, Arveux P, Milan C, Durand G, Lamour J, Bedenne L. Participation in mass screening for colorectal cancer: results of screening and rescreening from the Burgundy study. Eur J Cancer Prev 1991; 1: 49-55.
27. Tazi A, Faivre J, Lejeune C, Benhamiche AM, Dassonville F. Performances du test Hemoccult â dans le dépistage des cancers et des adénomes colorectaux. Résultats de cinq campagnes de dépistage en Saône-et-Loire. Gastroenterol Clin Biol 1999; 23: 575-580.